-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $22

Benzinga·05/05/2026 18:40:11
Listen to the news
Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $20 to $22.